Core Viewpoint - Nuveen Global High Income Fund has announced a rights offering to its common shareholders, allowing them to purchase additional shares at a discount to the market price, aimed at increasing the fund's assets and providing high current income to shareholders [1][2]. Group 1: Rights Offering Details - The Board of Trustees has approved the issuance of transferable rights to holders of common shares as of October 21, 2025, with the rights allowing shareholders to subscribe for new common shares at a subscription price expected to be below the market price [1][2]. - Record Date Shareholders will receive one right for each common share owned, with the rights allowing the purchase of one new common share for every four rights held (1-for-4) [3]. - The subscription price will be determined as 95% of the average of the last reported sales price on the NYSE on the expiration date and the four preceding trading days, with a minimum price set at 90% of the net asset value per common share [3]. Group 2: Benefits of the Offer - The rights offering is expected to enhance portfolio yields and fund earnings by taking advantage of attractive valuations in global high-income asset classes [2][3]. - The offering allows for tax-efficient rebalancing of the portfolio without selling existing positions, potentially reducing taxable events for shareholders [3]. - Increased trading volume and liquidity of common shares are anticipated as a result of the offering, along with a lower expense ratio due to spreading fixed operating costs across a larger asset base [3]. Group 3: Additional Information - The rights are transferable and will begin trading on the NYSE under the symbol "JGH RT" on October 20, 2025, with regular trading expected to start on October 23, 2025 [3][4]. - Monthly distributions are expected to be declared for November and December 2025, with shares issued from the rights offering not eligible for the earlier distributions [4]. - The final terms of the offer will be detailed in a prospectus supplement, which will control over the initial announcement [5].

Orsted A/S raised 60 billion Danish kroner ($9.4 billion) through a rights offering that’s critical for the company to tackle the downturn facing the wind power industry https://t.co/9sMjDk8P2Q ...

Group 1 - The article provides a market analysis covering major companies including Microsoft Corporation, Alphabet Inc Class A, Amazon.com Inc, and Southern Company [1] - It highlights the performance trends and investment opportunities within these companies [1] - The analysis is available on Investing.com, indicating a resource for investors seeking detailed insights [1]

Core Viewpoint - Prime Drink Group Corp. has terminated its rights offering and is moving forward with a non-brokered private placement to raise a maximum of $5,000,000 [1] Group 1: Private Placement Details - The private placement will offer units at a price of $5,000 per unit, each consisting of 62,500 common shares and 62,500 transferable share purchase warrants [2] - A maximum of 62,500,000 common shares will be issued at a deemed price of $0.08 per share, along with a maximum of 62,500,000 warrants [2] - Each warrant allows the holder to purchase a common share at $0.085 for two years from the issuance date [2] Group 2: Financial Aspects - The company will pay a cash finders' fee of 6% on the proceeds received from subscribers introduced by arm's-length finders [3] - The net proceeds from the unit offering will be used for business development and general working capital purposes [5] Group 3: Regulatory and Compliance - The units are offered through private placement exemptions from prospectus requirements under applicable securities laws, with resale restrictions including a hold period of four months and one day [4] - The offering is subject to final approval from the Canadian Securities Exchange and other regulatory approvals [4] Group 4: Company Overview - Prime Drink Group Corp. is based in Québec and aims to become a leading diversified holding company in the beverage, influencer media, and hospitality sectors [6]

Core Viewpoint - Asia Pacific Wire & Cable Corporation Limited has filed a Registration Statement for a proposed rights offering to raise approximately $34.2 million in equity capital, primarily for new production facilities [1][2]. Group 1: Rights Offering Details - The rights offering aims to provide all shareholders the opportunity to participate on a pro rata basis [2]. - Shareholders will receive non-transferable subscription rights at a ratio of one right per common share, allowing them to purchase additional shares at a subscription price of $1.66 each [3]. - An over-subscription right will be available, permitting rights holders to purchase additional shares that remain unsubscribed after the initial offering [4]. Group 2: Shareholder Participation - The controlling shareholder, Pacific Electric Wire & Cable Co., Ltd. (PEWC), intends to invest at least $27.7 million in the rights offering, although there is no guarantee of participation [5]. Group 3: Regulatory and Procedural Information - The rights offering will not commence until the Registration Statement is declared effective by the SEC, with further details to be provided in the final prospectus [6]. - The record date and subscription period will be announced once established [6]. Group 4: Company Overview - Asia Pacific Wire & Cable Corporation Limited is a holding company based in Bermuda, primarily engaged in manufacturing and distributing enameled wire, power cable, and telecommunications products across the Asia Pacific region [8]. - The company also provides project engineering services related to power cable supply and installation, serving various major customers including appliance manufacturers and electrical contracting firms [8].

Group 1 - The Board of Directors of Total Return Securities Fund, Inc. plans to authorize the issuance of non-transferable rights for shareholders to purchase additional shares at 85% of the net asset value on the expiration date [1] - Following the rights offering, the Board intends to authorize a tender offer to purchase either 30% of the Fund's outstanding shares if at least 8 million shares are issued, or the greater of 15% of outstanding shares or a number that results in approximately $90 million in net assets if fewer than 8 million shares are issued [2]

Core Viewpoint - NXG NextGen Infrastructure Income Fund successfully completed a transferable rights offering, which was oversubscribed, raising approximately $63 million for investment in infrastructure-related securities [1][2]. Group 1: Offering Details - The rights offering commenced on July 21, 2025, and expired on August 13, 2025, allowing rights holders to subscribe for up to 1,414,904 common shares at a subscription price of $44.92 per share [1]. - The subscription price was set at 90% of the Fund's net asset value per share at the close of trading on the expiration date [1]. - Common shares will be issued after the completion of pro-rata allocation and receipt of all shareholder payments [1]. Group 2: Fund Objectives and Strategy - The Fund aims for a high total return with an emphasis on current income, investing at least 80% of its net assets in equity and debt securities of infrastructure companies [5]. - The investment focus includes energy, industrial, sustainable, and technology infrastructure companies, with a limit of 25% of managed assets in energy master limited partnerships [5]. - The Fund employs leverage as part of its investment strategy, although there is no assurance that it will achieve its investment objectives [6]. Group 3: Fund Management - NXG Investment Management, based in Dallas, Texas, serves as the investment adviser for the Fund, focusing on long-term growth in sustainable and traditional infrastructure sectors [4]. - The Fund is a closed-end management investment company, and its shares are traded on the New York Stock Exchange under the symbol "NXG" [5].

Core Viewpoint - IceCure Medical Ltd. has completed its rights offering, allowing shareholders to purchase up to 10,000,000 units at a subscription price of $1.00 per unit, generating approximately $10 million in gross proceeds [1][5]. Rights Offering Details - The subscription period for the rights offering expired on July 28, 2025, at 5:00 p.m. Eastern Time [1]. - Each holder of ordinary shares received one subscription right for every share owned, allowing them to subscribe for 0.1703 of a unit, which includes one ordinary share and a warrant [2]. - Holders who fully exercised their basic subscription rights could subscribe for additional units that remained unsubscribed [3]. Subscription Results - A total of 10,000,000 units were validly subscribed during the rights offering, with 4,627,771 units expected to be issued under the over-subscription privilege [4]. - The company plans to deliver the ordinary shares and warrants to rights holders on or about July 30, 2025 [4]. Financial Implications - The estimated gross proceeds from the rights offering are approximately $10 million, excluding related expenses [5]. Company Overview - IceCure Medical develops minimally-invasive cryoablation technology for tumor destruction, focusing on breast, kidney, bone, and lung cancers [10].

Core Viewpoint - IceCure Medical Ltd. is conducting a Rights Offering that allows existing shareholders to purchase units at a subscription price of $1.00 per unit, with the subscription period expiring on July 28, 2025 [1][6]. Group 1: Rights Offering Details - The Company distributed non-transferable subscription rights to holders of its ordinary shares as of July 9, 2025, allowing them to purchase up to 10,000,000 units at a price of $1.00 per unit [2]. - Each holder of the Company's ordinary shares will receive one subscription right for every share owned, with each subscription right entitling the holder to purchase 0.1703 of a unit, which includes one ordinary share and a warrant [6]. - The Rights Offering is being managed by Maxim Group LLC, and all inquiries regarding the offering can be directed to them [7]. Group 2: Subscription Process - Rights holders must contact their brokers or nominees to exercise their subscription rights and submit payment by the deadline, which may be set earlier than July 28, 2025 [3]. - The subscription rights will expire if not exercised by the specified deadline, and no fractional subscription rights or units will be issued [6]. Group 3: Company Overview - IceCure Medical develops and markets advanced cryoablation therapy systems for tumor destruction, focusing on breast, kidney, bone, and lung cancers [12]. - The Company's flagship product, the ProSense® system, is marketed globally and offers a minimally invasive alternative to surgical tumor removal [12].

Core Points - Atico Mining Corporation successfully closed its rights offering, raising gross proceeds of $3,287,572.42 by issuing 29,887,022 units at a subscription price of $0.11 per unit [1][3] - Each unit consists of one common share and one transferable common share purchase warrant, which can be exercised at $0.18 per share for two years [2] - Approximately 41% of the total rights units were issued to insiders, with the remaining rights expiring unexercised [3] Financial Details - The rights offering resulted in the issuance of 11,219,319 units through the basic subscription privilege and 18,667,703 units through the additional subscription privilege [3] - Following the offering, the total number of common shares outstanding is 151,173,207 [3] Future Plans - The company plans to utilize the net proceeds from the rights offering and an upcoming LIFE offering for the development of the La Plata project in Ecuador, additional drilling at the El Roble mine in Colombia, and general corporate purposes [5][4]